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Neurofibromatosis 1 is a genetic disease characterized by 
various symptoms such as dermatological, neurological and 
bone complications. This study presents the frequencies of 
complications requiring medical treatment in patients with 
neurofibromatosis. Our data suggest that most frequently 
treated symptoms were dermatological complications. It 
is important to know the characteristic complications re-
quiring treatment in order to provide appropriate care for 
patients suffering from neurofibromatosis. 
Neurofibromatosis 1 has various complications. To 
elucidate the frequency of neurofibromatosis 1-rela-
ted major complications requiring medical interven-
tion, a nationwide retrospective study was conducted 
of 3,530 patients with neurofibromatosis 1 registe-
red from 2001 to 2014 in Japan. The ratio of certified 
patients requiring medical intervention (>stage 3) 
was 82%. Patients classified in the most severe grade 
experienced dermatological complications (71.8% of 
patients), neurological complications (38.1%) and 
bone complications (33.3%). In patients with der-
matological manifestations, medical treatment was 
needed for cutaneous neurofibromas (58%), diffuse 
plexiform neurofibromas (31%) and malignant pe-
ripheral nerve sheath tumours (10%). Patients with 
neurological manifestations needed medical treat-
ment mainly for brain tumours (53%) and intellectual 
disability (26%). Patients with bone manifestations 
needed medical treatment for pseudoarthrosis (9%), 
scoliosis (55%) and bone defects (16%). It is neces-
sary for physicians to be aware of neurofibromatosis 
1-related complications requiring medical interven-
tion in order to provide appropriate care for patients 
with neurofibromatosis 1.
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Neurofibromatosis 1 (NF1) is an autosomal dominant genetic disorder with a birth incidence of 1 in 3,000–
4,000 individuals (1). NF1 is caused by a mutation of the 
NF1 gene (2) and has various complications, including 
dermatological, neurological and bone manifestations 
(3). We recently performed an epidemiological survey 
of patients with NF1 at the Division of Dermatology of 
Tottori University Hospital in Japan for assessment of 
disease severity. The survey found that 37.1% of patients 
had major health impairments requiring medical treat-
ment (4). In addition, two-thirds of patients classified 
in the most severe grade of NF1 experienced diffuse 
plexiform neurofibromas with secondary problems. How-
ever, the number of patients in that study was relatively 
small (n = 124) and the survey was limited to the field of 
dermatology. Since patients with a severe grade of NF1 
have been supported by the public medical expenses 
subsidy system in Japan, we investigated the details of 
complications in cases requiring medical intervention 
that were registered in a national database. The aim of 
this nationwide study was to elucidate the clinical cha-
racteristics of NF1 and to determine the frequencies of 
complications requiring medical intervention.
PATIENTS AND METHODS
This retrospective study investigated clinical information for 
patients with NF1 registered at the Ministry of Health, Labour 
and Welfare from 2001 to 2014 from all over Japan. Patients with 
NF1 with a certain grade of severity are registered for research and 
exemption of medical fees as a government’s healthcare policy 
in Japan. Anonymous data for patients who met the diagnostic 
criteria of NF1 by the National Institutes of Health in 1988 (5) 
were analysed (patients for whom essential information, such 
as age or sex, was missing were excluded). Clinical informa-
tion, including sex, age, family history and complications, was 
investigated. Clinical severity was also assessed by both the 
Japanese severity classification (DNB classification) (4) and 
Riccardi’s severity grade (6), as shown in Appendices S11 and 
S21. The study protocol was approved by the ethics committees 




Of the 3,530 registered patients, 25 were excluded from 
the study due to missing essential data. Finally, data for 
Epidemiological Analysis of Major Complications Requiring Medical 
Intervention in Patients with Neurofibromatosis 1
Yuichi YOSHIDA1, Yuko EHARA1, Monji KOGA2, Shinichi IMAFUKU2 and Osamu YAMAMOTO1
1Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Yonago, and 
2Department of Dermatology, Fukuoka University School of Medicine, Fukuoka, Japan
brought to you by COREView metadata, citation and similar papers at core.ac.uk
























































Y. Yoshida et al.754
www.medicaljournals.se/acta
3,505 patients (1,595 males and 1,910 females) were 
analysed (Table I). The ages of patients ranged from 0 
to 93 years, with a mean age of 38.3 years. The distribu-
tion of patients by decade of life is shown in Fig. 1. The 
prevalence peak was between 30 and 39 years of age. 
There was a family history of NF1 in 42.3% of patients. 
Grade of severity
Grades of severity of NF1 evaluated by the DNB clas-
sification in Japan and Riccardi’s classification are 
shown in Table I. The ratio of patients with stage 1 or 2 
(mild manifestations not requiring treatment) was 18% 
in both classifications. Since the definitions of stages 
1 and 2 were almost the same in both classifications, 
the percentages of patients were the same. The ratio of 
certified patients requiring medical intervention (> stage 
3) was 82%. In the DNB classification, 55% of patients 
were classified as the most severe grade. The ratio of 
patients with grade 4 in Riccardi’s classification was 
44%, because patients with severe bone manifestations 
were categorized as stage 3 in that classification.
Frequencies of complications requiring medical 
intervention
In Japan, patients with NF1 with major health impair-
ments (stages 3–5) have been supported by the public 
medical expenses subsidy system. At first, we focused 
on patients classified in the most severe grade (stage 
5). The patients experienced dermatological complica-
tions (71.8% of patients), neurological complications 
(38.1%) and bone complications (33.3%). Next, we 
investigated the frequencies of each complication in 
detail (stages 3–5). In patients with dermatological 
manifestations, medical treatment was needed for cu-
taneous neurofibromas (58%), diffuse plexiform neuro-
fibromas (31%) and malignant peripheral nerve sheath 
tumours (10%) (Fig. 2A). Patients with neurological 
manifestations needed medical treatment mainly for 
intellectual disability (26%) and brain tumours (53%) 
(Fig. 2B). Patients with bone manifestations needed 
medical treatment mainly for long-bone bowing with 
pseudoarthrosis (9%), scoliosis (55%) and bone defects 
(16%) (Fig. 2C).
Table I. Characteristics of patients with neurofibromatosis 1 (NF1) 
in this study population
Characteristics n
Sex Age, years (mean ± SD)
  Male 1,595 37.6 ± 20.9 
  Female 1,910 38.8 ± 19.7 
Total 3,505 38.3 ± 20.3
Family history
  Yes 1,484 
  No 1,312
  Unknown 709
DNB classification Riccardi’s classification, n 
  Stage 1 175 175
  Stage 2 447 447
  Stage 3 309 1,354
  Stage 4 663 1,529
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Fig. 1. Age of 3,505 individuals in this study population.
A          B            C
  
Fig. 2. (A) Dermatological manifestations requiring medical treatment (A, cutaneous neurofibromas; B, large plexiform neurofibroma with severe secondary 
problems; C, malignant peripheral nerve sheath tumour (MPNST). (B) Neurological manifestations requiring medical treatment (A, severe intellectual 
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Frequencies of other complications
Cardiovascular diseases (arterial aneurysm, pulmonary 
stenosis, arterial hypertension, moyamoya disease and 
cerebral infarction) were seen in 48 patients (1.4%). En-
docrinological diseases (pheochromocytoma and thyroid 
dysfunction) were seen in 7 patients (0.2%). Malignant 
neoplasms (breast cancer and gastrointestinal stromal 
tumour) were seen in 16 patients (0.5%). The frequency 
of patients with osteoporosis was unknown.
DISCUSSION
NF1 has various complications, including dermatologi-
cal, neurological and bone manifestations (7). However, 
clinical expression is variable in each individual and the 
degree of severity is not predictable. There have been 
a number of reports on the incidences of NF1-related 
complications (8–10). We have reported previously that 
approximately two-thirds of patients with NF1 had a 
relatively mild phenotype, and life-threatening com-
plications were shown to be less common in a recent 
epidemiological study (4). Patients with NF1 are usually 
followed clinically with no medical or surgical interven-
tion. However, it has been reported that the overall risk 
of malignancies in patients with NF1 is 2.7-times higher 
than that in the general population (11). In addition, the 
mean age at death in patients with NF1 is approximately 
15 years younger than that in healthy individuals (12). 
Therefore, medical treatment is necessary for patients 
with serious complications. To provide appropriate care, 
it is important to be aware of the frequencies of NF1-
related major complications requiring medical interven-
tion. In our study, the ratio of patients with a severe grade 
was higher than that in a past study (13). It is likely that 
patients with a severe grade in our study tended to be 
registered in the system.
More than 70% of the patients with NF1 in the most 
severe grade had dermatological manifestations requiring 
medical treatment. It is notable that 58% of the patients 
supported by the public medical expenses subsidy system 
needed treatment for cutaneous neurofibromas. Cuta-
neous neurofibromas usually develop during puberty and 
the incidence increases with age (14). They are always 
benign, but they influence the quality of life in patients 
with NF1 (15). These tumours can be removed if they 
cause problems in daily life or social activity. Diffuse 
plexiform neurofibromas are seen in approximately 
20% of patients with NF1, and they can also cause se-
rious disfigurement (4). They have a risk of malignant 
transformation, and sometimes cause life-threatening 
massive intra-tumour haemorrhage. Although a large 
diffuse plexiform neurofibroma is a therapeutic chal-
lenge, treatment by surgery or embolization is preferable 
(16). Indeed, 31% of the patients with dermatological 
manifestations in the present study needed treatment 
for diffuse plexiform neurofibromas. Clinical trials for 
treatment of diffuse plexiform neurofibromas are ongoing 
(17). In the future, novel medical therapies with recent 
targeted strategies may be useful for treatment of diffuse 
plexiform neurofibromas.
In our study population, the prevalence peak was 
between 30 and 39 years of age. We assume that those 
patients presented with cosmetic and social problems due 
to the above dermatological manifestations. In contrast, 
the ratio of patients with malignant peripheral nerve 
sheath tumours, the most frequent malignant neoplasm 
associated with NF1, was relatively low (18).
Neurological manifestations are also commonly seen 
in individuals with NF1 (3). Treatment for neurological 
complications was needed in 38.1% of patients in the 
most severe grade. Approximately half of the patients 
had brain tumours. In addition, one-quarter of the patients 
needed medical care for severe intellectual disability. 
Neurological examinations should be performed during 
annual monitoring in patients with NF1.
The ratio of patients with bone manifestations in need 
of medical treatment was 33.3% in the most severe grade. 
Specific bone manifestations associated with NF1 include 
long-bone bowing with pseudoarthrosis (19) and sphe-
noid wing dysplasia (20). However, the frequencies were 
not high. In contrast, scoliosis affects approximately 10% 
of patients with NF1 (21), even though it is not inclu-
ded in established diagnostic criteria for NF1 (5). Since 
more than half of the patients with bone manifestations 
needed medical treatment for scoliosis, attention must 
be paid to this complication. The frequency in patients 
with osteoporosis has not been elucidated in this study.
This nationwide survey revealed, for the first time, 
the frequency of major complications requiring medical 
intervention in patients with NF1 based on the DNB 
classification. In agreement with a previous report 
(13), the priority for medical intervention seems to be 
dermatological manifestations, especially cutaneous 
neurofibromas.
This study has a number of limitations. The study 
population is not totally representative of the general 
NF1 population, because patients without severe com-
plications may not be registered in the public medical 
expenses subsidy system. In addition, there is a possibi-
lity that clinicians who are not familiar with management 
of NF1 do not recommend registration in the system to 
patients. The outcome may be biased by the selection 
of severe complications. In Japan, several NF1-related 
complications, including cardiovascular diseases, endo-
crinological diseases and malignant neoplasms except 
malignant peripheral nerve sheath tumours, have not 
been included in the DNB classification. Therefore, 
those complications could be overlooked in the system.
In addition, the medical costs of each manifestation in 
this study could not be assessed. In 2000 it was reported 
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900 EUR in France, and that the costs for moderate and 
severe cases were higher than the costs for less severe 
cases (13). However, it is not easy to assess the financial 
cost because the insurance system or economic scale is 
different in each country. Despite these limitations, the 
current study provides important information for medical 
and social management of NF1.
In conclusion, once NF1-related complications pro-
gress, much effort is needed to improve the impaired 
quality of life of patients with NF1. It is important for 
physicians to be aware of the priority of NF1-related 
major complications requiring medical intervention.
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